

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



Castro, HE; Briceo, MF; Casas, CP; Rueda, JD (2012) The History and Evolution of the Clinical Effectiveness of Haemophilia Type A Treatment: A Systematic Review. *Indian journal of hematology & blood transfusion*, 30 (1). pp. 1-11. ISSN 0971-4502 DOI: <https://doi.org/10.1007/s12288-012-0209-0>

Downloaded from: <http://researchonline.lshtm.ac.uk/1567796/>

DOI: [10.1007/s12288-012-0209-0](https://doi.org/10.1007/s12288-012-0209-0)

Usage Guidelines

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

Indian Journal of Hematology and Blood Transfusion

The history and evolution of the clinical effectiveness of haemophilia type A treatment- A systematic review --Manuscript Draft--

Manuscript Number:	IJHB-D-12-00165
Full Title:	The history and evolution of the clinical effectiveness of haemophilia type A treatment- A systematic review
Article Type:	Review Article
Corresponding Author:	Hector Castro, M.D. Universidad Javeriana Bogota, Bogota COLOMBIA
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	Universidad Javeriana
Corresponding Author's Secondary Institution:	
First Author:	Hector Castro, M.D.
First Author Secondary Information:	
Order of Authors:	Hector Castro, M.D. Maria Fernanda Briceño Claudia Casas Juan David Rueda, M.D.
Order of Authors Secondary Information:	
Abstract:	<p>First evidence of cases of haemophilia dates from ancient Egypt, but it was when Queen Victoria from England in the 19th century transmitted this illness to her descendants, when it became known as the "royal disease". Last decades of the 20th century account for major discoveries that improved the life expectancy and quality of life of these patients. The history and evolution of haemophilia healthcare counts ups and downs. The introduction of prophylactic schemes during the 1970s have proved to be more effective than the classic on- demand replacement of clotting factors, nevertheless many patients managed with frequent plasma transfusions or derived products became infected with the Human Immunodeficiency Virus (HIV) and Hepatitis C virus during the 1980s and 1990s. Recombinant factor VIII inception has decreased the risk of blood borne infections and restored back longer life expectancies. Main concerns for haemophilia healthcare are shifting from the pure clinical aspects to the economic considerations of long term replacement therapy. Nowadays researchers' attention has been placed on the future costs and cost-effectiveness of costly long term treatment. Equity considerations are relevant as well, and alternative options for less affluent countries are under the scope of further research. The aim of this review was to assess the evidence of different treatment options for haemophilia type A over the past four decades, focusing on the most important technological advances that have influenced the natural course of this "royal disease".</p> <p>Key words: Hemophilia A, coagulation disorder, clotting factor disorder.</p>

The history and evolution of the clinical effectiveness of haemophilia type A treatment- A systematic review

Castro, HE. MD,MsC, DrPH (can)¹

Briceño, MF. MD²

Casas, CP. MD³

Rueda, JD.MD⁴

Address for correspondence: Hector Castro, Department of Clinical Epidemiology & Biostatistics, Medical School, Pontificia Universidad Javeriana, Carrera 7 # 40-62, Bogotá, Colombia, Tel. +57-1-3208320 ext. 2810

castro.hector@javeriana.edu.co

Total words: 8161

Total words of the abstract: 236

Total figures: 1

Total pages: 32

¹ Hector Castro, London School of Hygiene & Tropical Medicine; Assistant Professor, Department of Clinical Epidemiology and Biostatistics, Universidad Javeriana, Bogota, Colombia

² María Fernanda Briceño, Research assistant, Department of Clinical Epidemiology and Biostatistics, Universidad Javeriana, Bogota, Colombia

³ Claudia CasasHaematologist at Hospital San Ignacio and Hospital San José Fundación Universitaria de Ciencias de la Salud, Bogota Colombia

⁴ Juan David Rueda, MD. Research assistant, Department of Clinical Epidemiology and Biostatistics, Universidad Javeriana, Bogota, Colombia

1
2
3
4 **Introduction:**
5

6
7 Haemophilia accounts for a long historic pathway; some authors may argue the
8 first case dates from ancient Egypt (1), others state the first registered reference
9 comes from Hebrew texts from the II century A.D, these writings explicitly banned
10 circumcision for those children with a previous family history of at least two
11 deceased brothers due to haemorrhage after this procedure. In the 19th Century
12 Haemophilia became popular when Queen Victoria from England “transmitted” the
13 haemophilia A genetic inheritance to several royal houses in Europe, including her
14 latest son Leopold who died at the age of 30, after a bleeding episode due to a
15 mild knee trauma; by that time haemophilia became known as the "royal
16 disease"(2).
17
18
19
20
21
22
23
24
25

26 It is estimated that 1 per 5000- 10.000 male births is going to suffer haemophilia A.
27 (3,4) Debuting age, location and severity of bleeding depend on the activity level of
28 clotting factor VIII. Clinical categories of haemophilia are: patients with mild
29 deficiency (5 - 40% activity of factor VIII (FVIII)), usually tend to bleed only after
30 major surgical procedures, patients with moderate deficiency (1 - 5% activity of
31 FVIII) and severe (< 1% activity) usually become symptomatic after minor surgical
32 procedures or spontaneously. Around 70 - 80% of bleeding episodes affect the
33 joints leading to haemarthrosis and progressive haemophilic arthropathy as the
34 most important long time complication (3, 4).
35
36
37
38
39
40
41
42
43

44 The clinical spectrum of severe haemophilia has evolved throughout history from
45 being a catastrophic and highly fatal condition in the early 20th century to a chronic
46 and “manageable” disorder in recent decades. In 1940 the first successful medical
47 treatment for haemophilia was published in the Lancet, an 11 years old boy that
48 experienced a major bleeding episode after a squint surgery was experimentally
49 treated with a whole- blood transfusion and survived (2). Further advances in
50 transfusion technology achieved during World War II, eased access of
51 haemophiliac patients to blood or plasma transfusions, as a result life expectancy
52 reached in average 39,7 years (5).
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 Judith Poo in 1964 discovered that the cryoprecipitate fraction of plasma contained
5 proportionally greater quantities of FVIII (4). The new product could be transported
6 and administered by the patient himself reducing barriers to prompt therapy.
7 Mortality rates, scholar and work abstention significantly dropped and the
8 haemophilic patients reached an average life expectancy of 60 years (1). By 1970's
9 medium purity concentrates were authorized for commercialization. At the same
10 time Nilsson and Ahlberg in Sweden pioneered the regular administration of FVIII
11 in a prophylactic, these new circumstances raised life expectancy again, this time
12 to up to 68 years of age (1,4). Enhanced by the availability of new therapeutic
13 options, the easier methods of administration and the raising life expectancy,
14 plasma demand steadily grew throughout the following years. Solely in the U.S.
15 there was a pool of approximately 20.000 donors, most of them poor people getting
16 paid for this activity. Even though there was a boom in the rates of blood
17 donations, the screening process was far from systematic and some donors were
18 considered to be at greater risk of transmissible diseases than the general
19 population. Infusion and transfusion of plasma derivatives were not safe and
20 complications started to appear soon after (5).
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 In 1982 the first US haemophilic patient was reported as being infected with the
37 Human Immunodeficiency Virus (HIV) (6); this new discovery raised concern and
38 the led to further report of additional cases; HIV reached incidence rates of 60
39 cases per million in 1990 in the US and 1 case in every 7 people in the UK among
40 haemophilic population (6, 7). HIV accounted for a quarter of all causes of death
41 during the 1990's in Netherlands (8, 9). It has been estimated that 80% of all
42 deaths from the Acquired Immunodeficiency Syndrome (AIDS) occurred before
43 1995. It was only after the mid 1990's with the introduction of antiretroviral therapy
44 (ARVT) that HIV related mortality in the haemophilic patients dropped (10), a
45 Canadian study that monitored all causes of death in haemophilic patients between
46 1982- 2003 (n= 2427) showed a reduction in mortality rates due to HIV from 74,6%
47 during 1982- 1997 to 42,9% after ARVT introduction (6,11). By 1992 an estimated
48 of 60% of the US haemophilic patients, and 80% of all patients ever treated with
49 clotting factor concentrates were already infected with hepatitis C (12, 13).
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 During the mid-1980s the genetic sequence of FVIII gene was achieved to produce
5 recombinant factor VIII (rFVIII)(14). The new rFVIII did not require any type of
6 plasma for its production, first patient treated was reported in 1987. Since 1985
7 there have been no reports of viral transmission linked to the use of rFVIII in the
8 developed world; virally safe products for hepatitis C are also available from 1992
9 onwards (8, 13). With the development of this new replacement alternative the
10 prognosis of haemophilia has dramatically changed; for instance in UK life
11 expectancy for a mild to moderate haemophiliac rounds 70 years of age, very close
12 to that for general local population, whereas for severe cases of haemophilia it is
13 estimated to be at least 15 years less, similar findings have been reported for the
14 Dutch haemophilic population (15).
15
16
17
18
19
20
21
22
23
24
25

26 From the 1990s onwards risk of blood borne infections has been controlled with the
27 extended use of recombinant replacement therapy, as well as with the introduction
28 of more sensitive immunoassays for the serological markers associated with
29 transfusion-transmitted viruses (TTVs). Main concerns in the haemophiliac
30 community have changed, the development of inhibitors (a neutralizing
31 immunoglobulin directly acting against factor VIII) is a frequent and serious
32 complication that has captured researchers' attention; hence there is academic
33 interest on comparing different treatment options and their association with the
34 emergence of these antibodies. From 2000 onwards the main concerns of
35 researchers have been placed around the future costs and cost- effectiveness of
36 long term treatment. Equity considerations are relevant as well, and alternative
37 options for less affluent countries are under the scope of further research.
38
39
40
41
42
43
44
45
46
47
48
49

50 Most of the scientific evidence on haemophilia A treatment comes from High
51 Income Countries (HIC) (16), and although all the promising findings from new
52 technological developments, it is not yet clear if risks or complications will raise in
53 the near future for rFVIII users, or if the incremental costs derived from higher
54 survival rates and costly treatment options will lead to unsustainable health
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

systems. The question if there are any other therapeutic alternatives for less affluent countries becomes relevant.

This systematic review was undertaken to assess the evidence of different treatment options for haemophilia A, with special interest on how the major improvements over the last four decades have influenced the natural course of disease. Special attention was placed on the type and quality of published data, and results are presented decade by decade throughout these forty years.

1
2
3
4 **Methods:**
5

6
7 Publications considering the clinical effectiveness of different treatment options for
8 haemophilia A (including at least one of these dimensions: bleeding episodes,
9 frequency and importance of adverse effects, potential complications, quality of life,
10 cost - effectiveness, and cost – utility and the development of inhibitors) were
11 sought. The following search terms were used throughout the search: [hemophilia
12 A], [coagulation disorder], [clotting factor disorder], [clotting factor deficiency],
13 [clotting factor disease], [treat*], [therap*], [manage*], [current], [updat*], [novel],
14 [classic*], [traditional], [conventional], [health outcome], [Impact], [effect*], [quality
15 of life] taking into account headings and sub- headings.
16
17
18
19
20
21
22
23

24 Possible studies of interest were sought from Medline, Embase, health economics
25 and health technology assessment database, Ovid, ACP Journal Club, Cochrane
26 Controlled Trials Register, The Cochrane Database of Systematic Reviews,
27 Econlit. The Medline strategy is listed in **Appendix 1**. Three independent
28 researchers ran the search, a fourth researcher acted as peer reviewer and
29 provided additional sources of data from relevant published and grey literature
30 sources.
31
32
33
34
35
36
37

38 Inclusion criteria were: Systematic reviews of literature and meta- analysis,
39 randomized controlled trials, cohorts, case and control study, case study, economic
40 evaluations, review articles. Complete articles published in English from 1970
41 onwards were sought. 1970 was set as relevant date since it was the time of
42 starting use of plasma- derived clotting factors; studies of patients at all ages were
43 included, only those publications assessing treatment for haemophilia A
44 (regardless of severity, complications, type of treatment, age of diagnosis or
45 treatment initiation) were considered. Publications that described and/ or
46 compared the classic/ conventional vs. current/ updated therapeutic strategies for
47 haemophilia A were included.
48
49
50
51
52
53
54
55
56

57 Exclusion criteria were: publications considering patients with coagulation
58 disorders different than haemophilia A, publications addressing patients with
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

acquired haemophilia A (due to the clinical differences of presentation, natural course of disease, co-morbidities, and therapeutic response to usual treatment).

Quality control and assessment of data included, extraction and synthesis by three different reviewers with the aim to reduce potential bias, the PRISMA workflow was used to systematically assess papers retrieved and to control for duplication and eligibility criteria. Given the heterogeneity of studies and evidence a detailed qualitative quality assessment matrix was constructed considering date of publication, period of analysis, type of study. Studies were ranked based on quality. RCTs, Meta- analyses, Systematic reviews, Cohort studies fulfilling all criteria for internal validity according to the type of study were scored as ++; when findings came from case and control studies, case studies, observational studies fulfilling all criteria for internal validity according to the type of study, or from RCTs, Meta- analyses, Systematic reviews, Cohort studies partially fulfilling criteria for internal validity, they were rank as +; evidence from the grey literature or case-control studies, case studies, observational studies that did not fulfil any criterion for internal validity were scored 0. The table of evidence and the grading criteria is depicted in **Appendix 2**.

1
2
3
4 **RESULTS**
5

6
7 **Stock of available evidence:**
8

9
10 A total of 1755 articles were retrieved from the search as potentially relevant
11 references; 7 records were suggested by an expert in haemophilia to be added to
12 the total number of possible articles to be analysed; 1749 publications were
13 recognized after controlling for duplicates; after abstract scanning a total of 1607
14 articles were excluded because they did not specifically address the main topic
15 of research (only subjects with haemophilia A); after scoping for references that
16 described and/or compared different treatment options for haemophilia A, 142
17 relevant references were obtained; 50 full text articles were screened for eligibility
18 criteria and 12 full text were excluded with reasons, a total of 38 publications were
19 finally included in this qualitative analysis (See **Figure 1**). Available evidence by
20 decade, by treatment focus, and by type and quality of publication are presented
21 below. A summary of evidence is provided at the last part of the results section.
22
23
24
25
26
27
28
29
30
31
32

33
34
35 Insert **Figure 1**. Approximately right here.
36
37
38
39
40

41 **Major findings by decade:**
42
43

44 **The 1970's:**
45

46 No reference published during the period between 1970- 1979 was retrieved from
47 our search, notwithstanding we found five publications that included in their
48 analyses the changes, improvements and concerns related with the different
49 options of treatment for haemophilia A during this period of time. Four narrative
50 reviews and one cohort study referred to this decade, the main subjects of these
51 articles included: the evolution of treatment of haemophilia throughout history,
52 discussion of therapeutic options at that time, the perceived risks associated with
53 the use of blood products during the 1970's, the availability and possible benefits of
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 home- based blood transfusions, and the improvement of quality of life derived
5 from treatment. The cohort study reported the risk of inhibitors development in a
6 population of UK patients followed between 1977 and 1999, suggesting an inverse
7 association between early exposure to exogenous clotting factor and the
8 appearance of inhibitors in these patients during the 1970's.
9

10 11 12 13 14 15 **The 1980's:**

16
17 Despite no articles were found as published during this; four references account for
18 data from this period of time, they are all narrative reviews of the treatment options
19 for haemophilia during this decade. The major emerging concern was the onset of
20 communicable diseases transmitted via transfusion products used for the treatment
21 of haemophilia A, all the publications depicted the association between standard
22 treatment (cryoprecipitate) and the development of contagious diseases like AIDS,
23 Hepatitis C and Hepatitis non A non C, claimed for the need of safer screening in
24 the manufacturing process of products for haemophilia acre, and urged for
25 research and development for a new and safer blood- derived products. The first
26 case report of the clinical efficacy (case report with two patients) of rFVIII, fostered
27 the industrial production of rFVIII becoming publicly available in 1989.
28
29
30
31
32
33
34
35
36
37
38

39 **The 1990's:**

40
41 We found three publications from this decade. One cohort study described the
42 relationship between FVIII replacement characteristics and inhibitor development in
43 previously untreated patients between 1990-2000; this study concluded that
44 regular prophylaxis was associated with a 60% lower risk than on- demand
45 treatment (RR, 0.4; CI, 0.2-0.8) for developing inhibitors, and that inhibitor
46 occurrence appeared to be associated with the age of first exposure to treatment,
47 decreasing from 41% for those treated within the first month of age to 18% in those
48 treated after 18 months of age; one narrative review described two different clinical
49 approaches on minimizing or delaying inhibitor development, and a report from the
50 grey literature that presented rFVIII, as new therapeutic alternative for children with
51 severe haemophilia A. The development of recombinant products and the
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 appearance of inhibitors became major topics of research that led to academic
5 publications comparing the different available options.
6
7
8

9
10 **The 2000's:**

11 The stock of knowledge about haemophilia exponentially increased during this
12 decade, 32 publications were found in our search (80% of all references retrieved),
13 some of these articles accounted in their period of analysis for previous decades.
14 We sought two systematic reviews from this period of time about the cost-
15 effectiveness of treatment options in patient with inhibitors, and on the efficacy of
16 the immune tolerance treatment to control for it.
17
18
19
20
21
22
23

24 Three cohort studies were also found comparing different treatment options, the
25 type of factor VIII used (FVIII vs rFVIII), and the timeframe exposure and the
26 development of inhibitors; additionally twelve review articles, two randomized
27 clinical trials, one case and control study, one case study and one economic
28 evaluation were retrieved and appraised from this period, the dominant research
29 topic was the identification of risk factors for inhibitors development, and also
30 alternative comparison of different treatment options in patients with inhibitors, the
31 advantages of prophylaxis (primary and secondary) over on- demand therapy, the
32 comparison between alternative primary prophylaxis regimes in terms of
33 haemophilic arthritis prevention, the association between the number of bleeding
34 episodes and quality of life, the cost- effectiveness and the availability of alternative
35 regimes in developed and developing countries.
36
37
38
39
40
41
42
43
44
45
46
47

48 **2010 onwards:**

49
50
51 Five review articles and one systematic review have been published since 2010 up
52 to date (23rd September 2011), this publications discussed the role of prophylaxis
53 in the prevention of haemarthrosis in children with haemophilia, the sensed need to
54 establish a gold standard for primary prophylaxis, the alternative current options to
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 treat acute bleeding events in patients with inhibitors, and the available options to
5 treat mild haemophilia A.
6
7

8
9 **The report of evolving treatment strategies:**
10

11
12
13 None of the publications retrieved through the search was dedicated to on-
14 demand therapy entirely, nevertheless three articles (narrative reviews), described
15 the use of this approach during the 1970's and early 1980's, right before the
16 inception of recombinant technology, and before prophylaxis became current
17 practice, access barriers to prompt treatment in hospital settings are mentioned as
18 main disadvantages of this therapeutic scheme, delays between the initiation
19 treatment and the subsequent repercussions on the quality of life of patients are
20 discussed in a few of these articles; one case and control study unveiled the
21 differences in the quality of life between patients treated with on- demand vs. those
22 treated with primary prophylaxis in Europe favouring prophylaxis in terms of
23 physical functioning, less role limitations, bodily pain, general health, vitality, social
24 functioning, emotional role limitations, and overall mental health.
25
26
27
28
29
30
31
32
33
34
35
36

37 Three quarter of our reviewed articles primary focused on primary prophylaxis (a
38 total of thirteen articles were retrieved, seven narrative reviews, one cohort study,
39 one case and control study, one case study, one economic evaluation and two
40 reports from international conferences from the world federation of haemophilia
41 classified as grey literature). The main topics discussed by these papers were, the
42 need to decide on an international standard for primary and secondary
43 prophylaxis, the optimal age for initiation and duration of prophylactic treatment,
44 the advantages of prophylaxis in terms of prevention of haemarthrosis and
45 disability in the long term, and subsequently the positive impact of this approach on
46 the overall quality of life when compared with on- demand therapy; the
47 determinants and barriers to comply with treatment as well as the comparative
48 cost- effectiveness of prophylaxis and the possible financial limitations for its
49 instauration in developing countries.
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6 Just a limited number of articles were related to secondary prophylaxis, we found
7 two randomized clinical trials (RCTs) and one review article linked with this scheme
8 of treatment. One RCT enrolled 38 male patients with a high baseline bleeding
9 frequency (mean \pm 4 bleeds per month) in a pre- prophylaxis stage for a period of
10 three months. Twenty-two patients were randomized to receive daily rFVIIa
11 prophylaxis with either 90 or 270 IU per Kg during a period of 3 months, followed
12 by a 3-month post prophylaxis period. Bleeding frequency was reduced by 45%
13 and 59% during prophylaxis with 90 and 270 IU per Kg, respectively (P < 0.0001),
14 Patients reported significantly fewer hospital admissions and days absent from
15 work/school during prophylaxis compared to the pre-prophylaxis period. The
16 second RCT examined the role of secondary prophylaxis with rFVII in quality of life
17 improvement; rFVIIa prophylaxis significantly reduced bleeding frequency vs. prior
18 on-demand therapy (P < 0.0001). Hospital admissions (5.9% vs. 13.5%; p=
19 0.0026) and school/work absenteeism (16.7% vs. 38.7%; p= 0.0127) were reduced
20 during prophylaxis, and tended to remain during post- prophylaxis. The review
21 article referred to the benefits of secondary prophylaxis on joint damage
22 prevention, functional capacity and quality of life, suggesting it to be considered as
23 an alternative therapeutic option for patients that cannot or are not willing to
24 receive primary prophylaxis.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 Eight publications were focused on haemophilia type A with inhibitors treatment.
44 Two were systematic reviews; five were reviews articles and one a case study.
45 One of the systematic reviews and one review article summarised the best
46 available evidence on the clinical effectiveness to treat acute bleeding events in
47 haemophilia A patients with inhibitors, comparing high-doses of FVIII, Porcine FVIII
48 and Activated Prothrombin Complex Concentrates (APCC) with the final outcome
49 (control of spontaneous bleeding episodes and haemorrhages secondary to
50 surgery); one systematic review and one narrative review discussed the efficacy,
51 safety and effectiveness of the products currently available for immune tolerance
52 induction; one review article described the efficacy and effectiveness of rFVII as a
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 new option to treat patients with inhibitors in terms reducing inhibitor levels in the
5 short and long term; One review article compared the efficacy of different drugs
6 emphasising on the haemostatic effect of rFVIII and FEIBA, and the use of
7 prophylaxis with rFVIIa (surgical- and non-surgical settings) and the associated
8 reduction in the number of bleeding events and the improved quality of life. Finally
9 one case study described the use of Rituximab in a single dose for 3 patients with
10 high and low titter inhibitors, showing clinical improvement in terms of bleeding
11 frequency and inhibitor levels
12
13
14
15
16
17
18
19
20

21 **Type of publications and quality of evidence level:**

22
23
24 A total of 38 articles were qualified, three of them were classified as systematic
25 reviews (one ranked as middle quality and two as high quality of evidence). Only 2
26 randomized clinical trials were retrieved in our search (one classified as high level
27 of evidence and the second one combined with an economic study middle level).
28 More than a half of the publications were review articles (total number of 21), and
29 all of them were classified as middle quality of evidence. 5 cohort studies were
30 obtained (all of them were ranked as high quality). Two case studies (ranked as
31 middle level of quality of evidence). 3 economic evaluations retrieved (one was
32 ranked as middle level and combined with a RCT, and the other two were ranked
33 as high quality of evidence). 3 reports were retrieved from the grey literature, all of
34 them scored as low quality of evidence.
35
36
37
38
39
40
41
42
43
44

45
46 It was remarkable finding the lack of RCTs comparing different treatment options for
47 severe haemophilia A, perhaps derived from the ethical limitations of
48 randomization after prophylaxis proved to be clinically effective. During the 1970's
49 and 1980's although very limited, narrative reviews and grey literature dominated
50 the stock of knowledge with their subsequent prompt to bias. After the 1990's the
51 number of publications for haemophilia A have exponentially increased via reports
52 from cohort studies, systematic reviews and a few number of randomized
53 controlled trials. From the 2000 onwards quality of evidence has improved as well
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 as the number of cost- effectiveness and cost- utility analyses regarding this
5
6 condition.
7
8

9
10 **Summary of findings on treatment:**
11

12
13 Over the last four decades management of patients with haemophilia A has
14 experienced dramatic improvements, notwithstanding its ups and downs
15 throughout history. A wide range of therapeutic strategies have been developed
16 since the 1970 decade. On the one hand the conventional on- demand treatment,
17 consisting of missing factor supply after the onset of a bleeding episode, is an early
18 approach that despite an incredible improvement in life expectancy, accounted for
19 poor quality of life outcomes; access barriers to hospital provision of clotting factor,
20 and the subsequent joint damage from lack of prevention were pitfalls faced by
21 clinicians and patients (4).
22
23
24
25
26
27
28
29
30

31
32 In contrast, prophylaxis defined as a form of prevention has proven to be superior
33 in preventing bleeding events, and their subsequent sequelae. Although there are
34 several prophylactic schemes a consensus meeting of experts held in London in
35 2002, helped to define “primary prophylaxis” as a long-term continuous treatment
36 (intent of treating 52 weeks per year up to adulthood receiving treatment at a
37 minimum of 46 weeks per year), started before the age of 2 years and prior to any
38 clinically evident joint bleeding or before the onset of joint damage irrespective of
39 age (defined as having had no more than one joint bleed) (18). This prophylactic
40 replacement of clotting factor has been recommended as the gold standard of care
41 by the World Federation of Haemophilia (WFH) and the World Health Organization
42 (WHO).
43
44
45
46
47
48
49
50
51

52
53 Several studies retrieved from our search have demonstrated superior
54 effectiveness of primary prophylaxis in the reduction of bleeding frequency, hence
55 on preventing and reverting of haemophilic arthropathy vs. on- demand therapy.
56
57 The US Joint Outcome Study (JOS), the first randomized clinical trial that
58
59
60
61
62
63
64
65

1
2
3
4 compared prophylaxis and on- demand therapy, included 65 young children (<
5 than 30 months of age), who were randomized to receive prophylaxis vs. on-
6 demand treatment (infusions of 25 IU per Kg of FVIII every 2 days for prophylaxis
7 vs. on- demand treatment three or more infusions of factor VIII, using at least 80 UI
8 per Kg to treat articular bleeds), the annual mean incidence of bleeding episodes
9 was much less in the prophylaxis group compared to the on- demand group ($0.63 \pm$
10 1.35 vs. 4.89 ± 3.57 respectively $p < .001$), in addition 93% of patients allocated
11 in the prophylaxis group had normal joint indexes assessed by Magnetic
12 Resonance Imaging (MRI), in contrast to 55% of patients treated on- demand ($p =$
13 $.006$) (19). These results were backed by a prospective 10 year Italian trial
14 (ESPRIT), which enrolled 40 patients younger than 7 years of age with negative
15 clinical and radiological scores for joint damage; patients were randomized to be
16 treated with recombinant factor VIII (rFVIII) 25 IU kg three times a week or on-
17 demand (25 IU kg) until complete healing, results indicated that prophylaxis is
18 associated with significantly fewer breakthrough bleeds than on- demand treatment
19 (0.24 vs. 1.30 bleeds per month, respectively; $P < 0.001$) (19- 21). A retrospective
20 cohort analysis involving 156 Norwegian and Swedish patients suggested that
21 patients who received prophylaxis required fewer total invasive procedures than
22 those who received on- demand treatment (22). Less number of bleeding
23 episodes, and life threatening haemorrhages under prophylaxis, should be
24 associated with a much better joint status and a better quality of life. A European
25 study assessing Health related Quality of Life (HR-QoL) applied the Short-Form 36
26 (SF-36) which accounts for eight dimensions of HR-QoL to 1033 haemophilic
27 patients of 12 years of age with moderate to severe haemophilia, five of these eight
28 dimensions were significantly higher in HIV negative patients receiving prophylactic
29 therapy when compared to on- demand, these dimensions included, physical
30 functioning, bodily pain and mental health (20, 23).
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53
54
55 According to the literature, besides the benefit of haemophilic arthropathy
56 prevention from prophylaxis a marked reduction of intracranial haemorrhages,
57 lower muscular-skeletal pain, lower rates of inpatient admissions and average of
58
59
60
61
62
63
64
65

1
2
3
4 stay, improved school and work attendance and improved academic achievement
5 have been reported (18, 24). A starting age of treatment between 1 to 2 years of
6 age could be associated with no risk at all of developing haemarthrosis under
7 sustained treatment (18), a Dutch cohort study that evaluated the optimal age to
8 start prophylaxis demonstrated that an early start resulted in complete prevention
9 of joint damage for 70% of boys compared with 31% for boys who started
10 prophylaxis after 3 or more bleeds.
11
12
13
14
15
16
17

18
19 Approximately 10% of severe haemophiliacs do not bleed as frequently as would
20 be expected from their circulating factor levels (24). The JOS study suggests that
21 the occurrence of the first joint bleed rather than a specific age may represent a
22 reasonable criterion for starting prophylaxis (21). After two decades of follow up,
23 the radiological Pettersson joint score (a scoring system that increases based on
24 radiological evidence of haemophilic joint damage) was 8% higher for every year
25 prophylaxis was postponed after the first joint bleed, this data suggests that
26 primary prophylaxis should be started at an early age but can be individualized
27 based on the bleeding pattern of each individual (25).
28
29
30
31
32
33
34
35
36

37 A consensus about the best prophylaxis protocol is still undetermined. Primary
38 prophylaxis based on the Swedish protocol (also known as the high-dose Malmö
39 protocol) involves the administration of 20– 40 Factor VIII UI per Kg three times a
40 week, and is currently considered the gold standard of care. This protocol is
41 recommended by the WFH, WHO, the UK Haemophilia Centre Doctors
42 Organization and the Medical and Scientific Advisory Council of the US National
43 Haemophilia Foundation as the optimal treatment until a cure is available (25, 26).
44 Nevertheless there are several protocols available and still being used. The Dutch
45 intermediate-dose prophylaxis protocol supplies 15–25 factor VIII IU per Kg
46 infused two or three times a week and the subsequent prophylactic dose is
47 adjusted based on spontaneous breakthrough bleeding into joints and not
48 according to the subject body weight or trough levels of FVIII (25).
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 The Canadian approach was a dose-escalation scheme of primary prophylaxis
5 started in 1997. In this prospective study, boys at ages 1 year to 2,5 years with
6 severe haemophilia A, started on a once weekly infusion of FVIII (50 IU kg). If
7 clinically significant bleeding into muscles and/or joints occurred, the frequency of
8 FVIII infusion was increased to twice weekly (dose 30 IU kg); continuation of
9 bleeding resulted in escalation of the prophylaxis regimen up to 25 IU kg) on
10 alternate days. Criteria for escalation included: \geq 3 clinically determined bleeds into
11 any one joint over a consecutive 3-month period; \geq 4 significant soft tissue/joint
12 bleeds over a consecutive 3-month period and \geq 5 bleeds into any one joint while
13 on the same dosage (step) of factor therapy over any period of time (25, 27, 28).
14
15
16
17
18
19
20
21
22
23

24 Nonetheless all the possible options, the Swedish high-dose prophylaxis regimen
25 is associated with a significantly lower rate of joint bleeding in comparison with the
26 Dutch intermediate-dose regime; FVIII consumption and costs were approximately
27 twofold higher for the former scheme. After at least after 20 years of follow-up, the
28 extent of haemophilic arthropathy measured by a radiologic scale is similar for
29 these two prophylaxis regimens. In the Canadian study one-third of patients
30 appeared to be successfully maintained on a once per week prophylaxis regimen
31 for a considerable period of time without the need for escalation. This suggests that
32 rapid progression in treatment, as employed in the Swedish regimen may be
33 unnecessary in a small proportion of patients. Yet in the Canadian study several
34 patients developed target joints prior to the escalation of therapy. Furthermore,
35 despite the absence of life-threatening bleeds seen in the Canadian study, there is
36 a concern that with once weekly prophylaxis these patients remain at risk of
37 serious and even life-threatening bleeds for most of the time (29). Nevertheless
38 this approach might be less costly while infusing less factor concentrate than with a
39 traditional prophylaxis regimen, and also may reduce the need for a central venous
40 catheter (CVC), and hence its complications (infection or thrombosis). A problem
41 with this approach is that there are currently no standard criteria for determining
42 unacceptable bleeds. Moreover, the long-term joint outcome of this approach and
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 its protective effect against other serious bleeds is not known, because of the
5 infrequent once-weekly dosing in many patients (26).
6
7

8
9
10 There was no literature found in our search that supported the interruption of
11 prophylaxis in the adulthood, institutions like the WFH, The US national foundation
12 of haemophilia and the WHO recommend continuing prophylaxis in the adulthood,
13 because adults remain at risk of developing joint or other kind of bleedings. A
14 follow-up Dutch and Danish study showed that 28 out of 80 (35%) severe
15 haemophiliacs permanently discontinued prophylaxis in early adulthood. These
16 patients experienced on average 3.2 joint bleeds annually over the 3 years after
17 discontinuing prophylaxis. Patients who remained on prophylaxis experienced on
18 average 1.8 joint bleeds annually during the same time period (19, 24).
19 Paradoxically, limited evidence suggests that those patients who permanently
20 discontinued prophylaxis tended to have a milder bleeding pattern than those who
21 continued prophylaxis (27). According to one reference counselling for adolescents
22 and young adults about the consequences of abandoning primary prophylaxis is
23 essential to prevent complications (30).
24
25
26
27
28
29
30
31
32
33
34
35
36

37 Secondary prophylaxis is defined as a long-term continuous treatment not fulfilling
38 the criteria for primary prophylaxis (4, 18), and has the primary aim to reduce and
39 arrest joint bleeding and to halt the progression of joint destruction. It is intended to
40 reduce the risk of other serious haemorrhage, such as intracranial bleeds (31). In a
41 study of 21 patients receiving secondary prophylaxis at three different ages (1–2,
42 3–6 and >6 years), Kreuz et al found that although the number of joint bleeds
43 decreased significantly during prophylaxis in the two older groups, radiologic and
44 orthopaedic scores still deteriorated for those who reported more than five joint
45 bleeds before the initiation of prophylaxis, suggesting that once joint damage had
46 started, further joint deterioration could not be prevented by the initiation of
47 prophylactic therapy (26), even though secondary prophylaxis cannot reverse the
48 changes of chronic arthropathy, it may be beneficial by reducing frequency of
49 bleeding, hospital admissions and lost days from school or work, and by
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 decreasing damage progression. Patients treated with secondary prophylaxis had
5 a decreased number of joint bleeding episodes at the expense of higher clotting
6 factor concentrate consumption (4). A growing consensus among haemophilia
7 specialists is that an individualized protocol for each patient based on the bleeding
8 pattern and manifestations of the disease should guide decisions regarding the
9 prophylaxis regimen. Recent studies examining delayed initiation of secondary
10 prophylaxis are encouraging because they demonstrated that even delayed
11 prophylaxis can reduce the frequency of joint haemorrhages, lessen chronic joint
12 pain, enhance quality of life and, and when combined with aggressive
13 physiotherapy, may improve physical function and the radiographic appearance of
14 target joints (31).
15
16
17
18
19
20
21
22
23
24
25

26 There are several barriers for the use and the adherence to prophylaxis, a study of
27 patients at the Louisiana Comprehensive Haemophilia Care Center found lower
28 rates of adherence among patients receiving high-intensity treatment regimens
29 (32), of the 18 patients in the study's high-intensity group, only 3 (17%) had high
30 adherence (20). Some of the barriers that influence the adoption of and adherence
31 to prophylaxis are the cost and availability of clotting factors (accounting for about
32 80 – 90% of the total cost of treatment), prohibitive particularly for less affluent
33 communities (19). Six additional identified barriers to prophylaxis were (as
34 indicated by 30% of patients families in a study of 52 patients in the Mountain
35 States Regional Hemophilia and Thrombosis Center- Aurora, CO, USA): the
36 greater amount of venous access devices (required for long term treatments- three
37 folding on- demand regimens); the complications associated with those devices
38 (including infections and thrombosis); the need for therapy as perceived by the
39 patient; immediate social and family needs; parents inability to gain cooperation
40 from their young children, and specially the time required for prophylactic infusions.
41 These data suggest that products with higher dosages, longer half-lives or more
42 convenient mechanisms of infusion could improve adherence in patients with
43 haemophilia (20).
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 Notwithstanding the clear clinical effectiveness of prophylaxis, it also results more
5 costly with respect to on- demand treatment, Miners et al calculated an Incremental
6 Cost Effectiveness Ratio- ICER well above the £30 000 per QALY gained
7 threshold, when compared to on- demand therapy, a recent review of calculations
8 (adjusting clotting factor price, and long term effect of treatment) by the same
9 author estimated it is getting closer to being considered cost- effective (according
10 to NICE thresholds in the UK) (33).
11
12
13
14
15
16
17
18

19 Despite the consistent evidence about the benefits of prophylactic therapy, a
20 recent global survey of 147 haemophilia treatment centres (HTCs) throughout the
21 world showed that about a half of all patients with severe haemophilia A (54%) still
22 receive on-demand treatment, and only 19% are provided primary prophylaxis (20).
23 Even in High Income Countries- HIC, prophylaxis coverage is not universal, in the
24 US only 50% of severe haemophiliacs type A are treated under the gold standard
25 approach, this compared with 77% of patients in Canada (Universal Data
26 Collection (UDC) (31). The situation is much worse in emerging countries in which
27 the development of effective healthcare programs for haemophiliacs is still limited,
28 and where limited resources, the short availability of VIII factor concentrates means
29 an important barrier to provide prophylactic regimens.
30
31
32
33
34
35
36
37
38
39
40
41

42 After the improvement in safety of human derived blood products, the
43 development of recombinant factor concentrates and the subsequent reduction in
44 morbidity and mortality by blood- transmitted diseases, the development of
45 inhibitors (neutralizing antibody direct against FVIII), became the major concern of
46 in haemophilia care. In patients who develop inhibitors, the location and frequency
47 of bleeding episodes is usually similar to those who did not develop alloantibodies,
48 however, the prophylactic treatment is unfeasible and the treatment of acute
49 episodes is complicated, since inhibitors increase the rate of FVIII neutralization,
50 by partial or total reduction of its clinical activity (35, 36). Most centres consider
51 >0.6 Bethesda units (BU) as a positive result for having an inhibitor.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6 Several factors have been related to the development of inhibitors, the most
7 strongly associated is a type of genetic mutation of FVIII, as well as the type of
8 Human Leucocitary Antigen (HLA) and the polymorphisms in the genes codified for
9 cytokines (African or Hispanic background) of each individual (37), as well as the
10 type of replacement therapy used and the age of starting up. In a study by
11 Santagostino et al, 25 out of 108 children with haemophilia received prophylaxis
12 and had a lower inhibitor risk than those treated on- demand (adjusted OR 0.2; CI:
13 0.06–0.9), suggesting a protective effect of prophylaxis from inhibitor development.
14 A second study (Concerted Action on Neutralizing Antibodies in severe
15 haemophilia A- CANAL), 87 out of 386 (24%) previously untreated patients
16 receiving treatment for at least 50 consecutive days developed clinically relevant
17 inhibitors. Regular prophylaxis was associated with a 60% lower risk than on-
18 demand treatment (RR 0.4; CI, 0.2-0.8). Factors associated with an increased risk
19 of developing inhibitors included a high-intensity treatment at first exposure to FVIII
20 and high cumulative dose of FVIII during five consecutive treatment days. The
21 incidence of inhibitors appeared to be associated with age at first treatment,
22 decreasing from 41% for those treated within the first month of age to 18% in those
23 treated after 18 months (36, 38).
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 The CANAL study also reported the association of FVIII product type (i.e. plasma-
42 derived vs. recombinant) and switching between FVIII products with the risk of
43 developing inhibitor and concluded that neither plasma-derived FVIII products were
44 associated with a lower inhibitor risk than recombinant FVIII products, nor the
45 switching between FVIII product brands increased the inhibitor risk. In contrast a
46 cohort that evaluated 62 patients treated with the same brand of high-purity
47 plasma-derived FVIII (pFVIII) containing Von Willebrand factor (VWF) and 86
48 patients treated with full-length recombinant FVIII (rFVIII) concluded that the risk of
49 inhibitor development was higher in patients treated with rFVIII than in patients
50 treated with pFVIII, regardless of other risk factors (*F8* genotype; non-white origin;
51 history of inhibitors in patients with a family history of haemophilia; age at first FVIII
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 infusion). The adjusted relative risk (RR) for inhibitor development with rFVIII
5 versus pFVIII was 2.4 (17, 39).
6
7

8
9
10 In a retrospective a cohort study by Chalmers et al. assessed the incidence of
11 inhibitors in three hundred and forty-eight children with severe haemophilia A. They
12 found that 68 out of 348 (20%) developed inhibitors (10% corresponding to high
13 titer inhibitors). The incidence with regards to the age of initial FVIII exposure was:
14 26% in patients younger than 1 month, 25% in patient between 1- 6 months, 21%
15 between 6- 12 months, 20% in 12- 18 months and 9% in patients older than 18
16 months of age. A significant difference in inhibitor development and age at first
17 exposure across all age groups was found ($p= 0.018$), but no significant difference
18 was observed in children treated at different time points during the first year of life
19 ($p= 0.44$). In this study, exposure to FVIII during the neonatal period was not
20 associated with a higher incidence of inhibitors compared with those treated later
21 during the first year of life. Mortality associated with the development of inhibitors
22 has change through years, in severe haemophiliacs without HIV, inhibitor
23 development doubled mortality during 1977–92 in the UK, but during 1993–99
24 mortality was identical with and without inhibitors. In severe haemophiliacs without
25 HIV but with inhibitors, mortality from causes involving bleeding decreased during
26 1977–99 ($p= 0.001$) as did mortality involving intracranial haemorrhage ($p= 0.007$),
27 these results do not appear to be related with the type of treatment for haemophilia
28 or the treatment for the inhibitors. (40).
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45
46 Currently there is an increasing range of options to treat haemophilic patients with
47 inhibitors, these include: high doses of human factor VIII (FVIII), high purity factor
48 VIII (pFVIII);, By passing agents: (Prothrombin Complex Concentrates- PCCs),
49 Activated Prothrombin Complex concentrate (aPCCs)], Factor VIII bypassing
50 agent- FEIBA, Recombinant Factor VIIa (rFVIIa), and Immune tolerance therapy
51 these are further described in **Appendix 3**.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Acknowledgments

The authors want to acknowledge the logistic support of the school of medicine, Hospital San Ignacio and the Department of Clinical Epidemiology and Biostatistics for the logistic support to conduct the literature search.

Financial & competing interest disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest with the subject matter.

1
2
3
4 **Conclusions:**
5
6
7

8 Notwithstanding the ups and downs in the haemophilia care history, a sustained
9 success has emerged from the larger availability of safer plasma-derived and
10 recombinant replacement products from the late 1980s onwards, especially in the
11 develop world. Improvement in administration techniques and dosing regimens,
12 the introduction of home treatment, a progressive shift from on-demand treatment
13 to prophylaxis, the onset of antibodies inactivating the infused clotting factor
14 (inhibitors), and the further development of options to treat and possibly eradicate
15 them, account for this recent successful story.
16
17
18
19
20
21
22
23

24 The development of recombinant factor VIII potentially eliminates the risk of
25 infectious disease transmission, nevertheless a theoretical risk of transmitting
26 emerging non-viral pathogens such as the prion responsible for variant of the
27 Creutzfeldt Jakob disease (vCJD) still remains. With each new challenge a new
28 successful solution has emerged, all these developments have resulted in
29 increased life expectancy and health-related quality of life for haemophilic patients,
30 henceforth an illness with a different spectrum has emerged.
31
32
33
34
35
36
37
38

39 Literature has largely demonstrated the superior clinical effectiveness of
40 prophylaxis when compared with on- demand therapy. Data from the WFH and
41 WHO proved that prophylaxis is still distant to become universal, and for those
42 countries with the lowest per capita gross national product (GNP) haemophilia
43 healthcare is either inadequate, or there is no care at all. The impact of these
44 deficiencies in haemophilic patients' life expectancy and quality of life are expected
45 to be substantial. Currently, in emerging countries with lower incomes, the
46 implementation of prophylactic treatment programs seems unachievable,
47 especially with rFVIII. In this order of ideas, it remains as an important challenge to
48 improve access to prophylaxis in emerging communities.
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Further data and long-term studies are needed to determine whether a group of patients who can safely discontinue prophylaxis can be identified, hence procuring long term financial sustainability of health systems; additional robust cost-effectiveness studies comparing the current on- demand practice in developing countries with alternative prophylaxis regimes are also needed. Finally studies comparing different immune tolerance protocols will serve to determinate the best options in terms of efficacy, safety and cost- effectiveness for those societies able to afford it.

1
2
3
4 **REFERENCES:**
5
6
7

- 8 (1) Aledort LM (2007) History of haemophilia. *Haemophilia* 13 Suppl 5:1-2.
9
10 (2) Oldenburg J, Dolan G, Lemm G (2009) Haemophilia care then, now and in the
11 future. *Haemophilia* 15 Suppl 1:2-7.
12
13 (3) Stachnik J, Hemophilia: Etiology, complications, and current options in
14 management, *PharmD, BCPS: Formulary* July 2010: Vol. 45.
15
16 (4) Wong T, Recht M (2011) Current options and new developments in the
17 treatment of haemophilia. *Drugs* Feb 71(3):305-20.
18
19 (5) Lee CA (2009) The best of times, the worst of times: a story of haemophilia.
20 *Clin Med* 9(5):453-8.
21
22 (6) Evatt BL (2006) The tragic history of AIDS in the hemophilia population, 1982-
23 1984. *J Thromb Haemost* 4(11):2295-301.
24
25 (7) Mannucci PM (2003) AIDS, hepatitis and hemophilia in the 1980s: memoirs
26 from an insider. *J Thromb Haemost* 1(10):2065-9.
27
28 (8) Chorba TL, Holman RC, Strine TW, Clarke MJ, Evatt BL (1994) Changes in
29 longevity and causes of death among persons with hemophilia A. *Am J Hematol*
30 45(2):112-21.
31
32 (9) Ragni MV, Tegtmeier GE, Levy JA, Kaminsky LS, Lewis JH, Spero JA, et al.
33 (1986) AIDS retrovirus antibodies in hemophiliacs treated with factor VIII or factor
34 IX concentrates, cryoprecipitate, or fresh frozen plasma: prevalence,
35 seroconversion rate, and clinical correlations. *Blood* 67(3):592-5.
36
37 (10) Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio MA, et al.
38 (2003) Decline in the AIDS and death rates in the EuroSIDA study: an
39 observational study. *Lancet* 362(9377):22-9.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4 (11) Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Porter K, et al.
5 (2003) Determinants of survival following HIV-1 seroconversion after the
6 introduction of HAART. *Lancet* 362(9392):1267-74.
7
8
9
10 (12) Makris M, Garson JA, Ring CJ, Tuke PW, Tedder RS, Preston FE (1993)
11 Hepatitis C viral RNA in clotting factor concentrates and the development of
12 hepatitis in recipients. *Blood* 81(7):1898-902.
13
14
15 (13) Van der Poel CL, Reesink HW, Mauser-Bunschoten EP, Kaufmann RH,
16 Leentvaar-Kuypers A, Chamuleau RA, et al. (1991) Prevalence of anti-HCV
17 antibodies confirmed by recombinant immunoblot in different population subsets in
18 The Netherlands. *Vox Sang* 61(1):30-6.
19
20
21 (14) Mannucci PM, Tuddenham EG (2001) The hemophilias--from royal genes to
22 gene therapy. *N Engl J Med* 344(23):1773-9.
23
24
25 (15) Larsson SA (1985) Life expectancy of Swedish haemophiliacs, 1831-1980. *Br*
26 *J Haematol* 59(4):593-602.
27
28
29 (16) Prabhu R (2010) Novel strategies to Improve Recombinant Factor VIII
30 Production and its in vivo Recovery. *Indian J Hematol Blood Transfus.* 26(3):124-5.
31
32
33 (17) Farrugia A, (2002) Evolving perspectives in product safety for haemophilia.
34 *Haemophilia* 8(3): 236-43.
35
36
37 (18) Berntorp E, Astermark J, Bjornmarkman VS, Blanchette K, Fisher K (2003)
38 Consensus perspectives on prophylactic therapy for haemophilia: summary
39 statement. *Haemophilia* 9 Suppl 1: 1-4.
40
41
42 (19) Franchini M, Coppola A, Molinari AC, Santoro S, Schinco V, Speciale V,
43 Tagliaferri A (2009) Forum on: the role of recombinant factor VIII in children with
44 severe haemophilia A. *Haemophilia* 15(2): 578-86.
45
46
47 (20) Berntorp E (2009) Joint outcomes in patients with haemophilia: the importance
48 of adherence to preventive regimens. *Haemophilia* 15(6): 1219-27.
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4 (21) Santagostino E, Mancuso ME (2008) Prevention of arthropathy in
5 haemophilia: prophylaxis. *Haemophilia* 14 Suppl6: 16-19.
6
7
8
9 (22) Petrini P (2007) Identifying and overcoming barriers to prophylaxis in the
10 management of haemophilia. *Haemophilia* 13 Suppl 2: 16-22.
11
12
13 (23) Royal S, Schramm W, Bertntorp E, Giagrande A, Gringeri A, Ludlam C,
14 Kronker B, Szucs T (2002) Quality-of-life differences between prophylactic and on-
15 demand factor replacement therapy in European haemophilia patients.
16 *Haemophilia* 8(1): 44-50.
17
18
19 (24) Carcao MD, Aledort LM (2007) The Round Table Group "Prophylaxis in the
20 haemophilia population-optimizing therapy". *Haemophilia* 13(3): 227-32.
21
22
23 (25) Blanchette VS (2010) Prophylaxis in the haemophilia population. *Haemophilia*
24 16 Suppl 5: 181-88.
25
26
27 (26) Petrini P (2007) Identifying and overcoming barriers to prophylaxis in the
28 management of haemophilia. *Haemophilia* 13 Suppl 2: 16-22.
29
30
31 (27) Dunn AL (2005) Management and prevention of recurrent hemarthrosis in
32 patients with hemophilia. *Current Opinion in Hematology* 12(5): 390-94.
33
34
35 (28) Feldman BM (2006) Tailored prophylaxis in severe hemophilia A: interim
36 results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis
37 Study. *J Thromb Haemost* 4(6): 1228-36.
38
39
40 (29) Carcao M, Chambost H, Ljung R (2010) Devising a best practice approach to
41 prophylaxis in boys with severe haemophilia: evaluation of current treatment
42 strategies. *Haemophilia* 16 Suppl 2:4-9.
43
44
45 (30) Valentino L (2009) Controversies regarding the prophylactic management of
46 adults with severe haemophilia A. *Haemophilia* 15 Suppl 2: 5-22.
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 (31) Valentino L (2004) Secondary prophylaxis therapy: what are the benefits,
5 limitations and unknowns?. Haemophilia 10(2): 147-57.
6
7

8
9 (32) Dimichele D, Rivard G, Hay A, Antunes S (2004) Inhibitors in haemophilia:
10 clinical aspects. Haemophilia Supplement State of the Art XXVIth International
11 Congress of The World Federation of Hemophilia 10 Supplement 4: 140-45.
12
13

14
15 (33) Miners A (2009) Revisiting the cost-effectiveness of primary prophylaxis with
16 clotting factor for the treatment of severe haemophilia A. Haemophilia 15(4): 881-
17 87.
18
19

20
21 (34) Tusell J, Perez-Bianco R (2002) Prophylaxis in developed and in emerging
22 countries. Haemophilia 8(3): 183-88.
23
24

25
26 (35) Carcao M, Lambert T (2010) Prophylaxis in haemophilia with inhibitors: update
27 from international experience. Haemophilia 16 Suppl 2: 16-23.
28
29

30
31 (36) Lloyd M, Wight JS, Paisley S, Night C (2003) Control of bleeding in patients
32 with haemophilia A with inhibitors: a systematic review. Haemophilia 9(4): 464-520.
33
34

35
36 (37) Dimichele D (2007) Immune tolerance therapy for factor VIII inhibitors: moving
37 from empiricism to an evidence-based approach. J Thromb Haemost 5 Suppl 1:
38 143-50.
39
40

41
42 (38) Gouw SC, van der Bom JG, Marijke vdB (2007) Treatment-related risk factors
43 of inhibitor development in previously untreated patients with hemophilia A: the
44 CANAL cohort study. Blood 109(11): 4648-54.
45
46

47
48 (39) Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T,
49 Chambost H, Borel-Derlon A, Claeysens S, Laurian T, Calvez, T (2006) Influence
50 of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in
51 previously untreated patients with severe hemophilia A. Blood 107(1): 46-51.
52
53

54
55 (40) Darby SC, Keeling DM, Spooner RJ, Wan KS, Giangrande PL, Collins
56 PW, Hill FG, Hay CR (2004) The incidence of factor VIII and factor IX inhibitors in
57
58
59
60
61
62
63
64
65

1
2
3
4 the hemophilia population of the UK and their effect on subsequent mortality, 1977-
5 99. *J Thromb Haemost* 2(7):1047-54.
6
7

8
9 (41) Von Depka M (2005) Managing acute bleeds in the patient with haemophilia
10 and inhibitors: options, efficacy and safety. *Haemophilia* 9 Supplement 1: 18-23.
11
12

13
14 (42) Astermark J, Santagostino E, Hoots Wk (2010) Clinical issues in inhibitors.
15 *Haemophilia* 16 Suppl 5: 54-60.
16
17

18
19 (43) Konkle BA, Ebbesen LS, Erhardtsen E, Bianco RP, Lssitchkov T, Rusen L,
20 Serban (2007) Randomized, prospective clinical trial of recombinant factor VIIa for
21 secondary prophylaxis in hemophilia patients with inhibitors. *J Thromb Haemost*
22 5(9): 1904-13.
23
24


25
26 (44) Hoots WK, Ebbesen LS, Konkle BA, Auerswald GK, Roberts HR, Weatherall
27 J, et al. (2008) Secondary prophylaxis with recombinant activated factor VII
28 improves health-related quality of life of haemophilia patients with inhibitors.
29 [Article]." *Haemophilia* 14(3): 466-75.
30
31
32

33
34 (45) Wight J, Paisley S, Knight C (2003) Immune tolerance induction in patients
35 with haemophilia A with inhibitors: a systematic review. *Haemophilia* 9(4): 436-63.
36
37

38
39 (46) Aleem A, Saidu A, Abdulkarim H, Al-Diab AR, Al-Sagheer A, Qayum A, et al.
40 (2009) Rituximab as a single agent in the management of adult patients with
41 haemophilia A and inhibitors: marked reduction in inhibitor level and clinical
42 improvement in bleeding but failure to eradicate the inhibitor. *Haemophilia* 15(1):
43 210-16.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1. Prisma flow diagram systematic review on hemophilia A.



Supplementary Material

[Click here to download Supplementary Material: APPENDIX 1.docx](#)

Supplementary Material

[Click here to download Supplementary Material: Appendix 2.docx](#)

Supplementary Material

[Click here to download Supplementary Material: APPENDIX 3.docx](#)



Bogota, July 2, 2012

Editor in Chief
Indian Journal of Hematology and Blood Transfusion Health

Dear Editor:

Please consider for the publication in your journal our paper titled: **The history and evolution of the clinical effectiveness of haemophilia type A treatment- A systematic review**

As corresponding author I certify that the article is original, is not under consideration by any other journal, and has not been previously published. All authors comply with authorship requirements established by ICMJE. All copyright ownership of the manuscript entitled (The history and evolution of the clinical effectiveness of haemophilia type A treatment- A systematic review) is hereby transferred to the publishers of the Indian Journal of Hematology and Blood Transfusion Health

.

Yours,

Hector Castro
Corresponding author

Facultad de Medicina – Departamento de Epidemiología Clínica y Bioestadística

Carrera 7 No. 40-62 Piso 2°. Teléfono: (571) 3208320 Ext. 2799. Fax: (57-1) 2856981. Bogotá, Colombia